NBIX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
NBIX is a good buy right now for a beginner with a long-term horizon and $50,000-$100,000 to invest. The stock is showing a constructive pre-market setup, solid bullish technicals, strong recent analyst support, and improving fundamental momentum from Ingrezza, Crenessity, and the Soleno acquisition. I would rate it a buy, not a wait-and-see name, because the current setup still looks favorable for entering now.
NBIX is in a clear short-term bullish trend. The stock is up 0.96% pre-market at 157, above the pivot at 155.949 and close to resistance at 160.858. The MACD histogram is positive at 0.596, though mildly contracting, which still supports upward momentum. RSI_6 is 62.786, showing strength without being overbought. The moving averages are aligned bullishly with SMA_5 > SMA_20 > SMA_200, which is a strong trend confirmation for a long-term buyer. Overall, the chart supports continued upside, with near-term resistance in the 160.86-163.89 area and support in the 151.04-148.01 zone.
Recent catalysts are clearly positive. Neurocrine presented APA data showing 96% of patients with mild tardive dyskinesia improved after starting INGREZZA, which supports product strength and physician confidence. The company also completed its $2.9 billion acquisition of Soleno Therapeutics, adding VYKAT XR and diversifying revenue streams. Analyst commentary highlights stronger-than-expected Q1 sales for both Ingrezza and Crenessity, and several firms raised price targets. This creates a favorable event-driven backdrop for the stock.
The main negatives are valuation sensitivity and limited near-term catalyst breadth beyond commercial execution. Analyst notes mention 2026 as a relatively light pipeline catalyst year, meaning upside depends heavily on execution rather than major binary pipeline events. The stock also sits near short-term resistance, so gains may be gradual. Still, there are no major negative news shocks in the provided data.
Financial data was not fully available because the snapshot returned an error, so the latest quarter figures cannot be assessed directly. However, the analyst commentary indicates strong Q1 operating momentum. In particular, both Ingrezza and Crenessity sales exceeded expectations, and management commentary was strong enough for multiple firms to raise targets. Based on that, the latest quarter appears to have shown healthy growth trends, especially in commercial sales. Latest quarter season: Q1 2026.
Analyst sentiment is constructive and improving. Recent price target moves were mostly upward: JPMorgan raised PT to 185 with Overweight, Truist raised to 155 with Buy, Morgan Stanley to 191 with Equal Weight, Oppenheimer to 230 with Outperform, Piper Sandler to 207 with Overweight, Citi to 246 with Buy, and BofA to 199 with Buy. Deutsche Bank also raised its target to 155 but kept Hold. The overall Wall Street view is bullish to moderately bullish, with multiple firms citing strong Q1 commercial execution, improving setup, and attractive risk/reward. The main downside is that one or two firms remain neutral/hold-rated, so the consensus is positive but not unanimous.
